Alcami announced the sale of its preclinical and early stage active pharmaceutical ingredient (API) facility in Weert, Netherlands to MercachemSyncom, a mid-sized European integrated drug-discovery and development contract research organization. Terms were not disclosed.
“This transaction represents another key step in the strategic development of Alcami’s service delivery platform, focusing investments across our network toward high-growth market segments,” said Alcami Chief Commercial Officer Chad Telgenhof. “Additionally, our European sales and business development team will remain with our organization and continue to serve a strong and growing pipeline of Europe-based clients who are partnered with Alcami in the development and commercialization of their products.”
In December, the company announced a 6,000 square foot expansion at its facility in Charleston, South Carolina, which will augment the capacity of Alcami’s sterile drug product development and manufacturing operations. The $17 million investment is expected to create 30 new jobs in Charleston and be completed in 2021.